[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oxycodone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oxycodone":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,73,96,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100571571","effect-of-preventive-analgesia-with-oxycodone-and-parecoxib-sodium-on-the-chronification-of-acute-post-operative-pain-100571571",false,"NCT06721988","Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Post-operative Pain","Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery","AOPC","Inclusion Criteria:\n\n* ASA I\\~III；\n* BMI ranging from 18 to 28 kg\u002Fm²；\n* For elective laparoscopic-assisted major abdominal surgery under general anesthesia;\n* Estimated surgical duration (from incision to the last suture of the skin) was at least 2 hours.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients;\n* Patients diagnosed with septic shock or multiple organ failure within 14 days;\n* Patients with preoperative severe electrolyte disorders;\n* Patients with stroke, transient ischemic attack, or other similar events within the past 3 months\n* Patients with unstable angina, myocardial infarction within the past 3 months; or presence of untreated arrhythmia or arrhythmia not well-controlled with treatment;\n* Patients with diabetes, uncontrolled blood glucose levels, or diabetes complications such as diabetic ketoacidosis, hyperosmolar coma, diabetes-related infections, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic peripheral neuropathy, diabetic foot, etc. before the surgery;\n* Patients with severe liver dysfunction (Child-Pugh score \\> 6), renal dysfunction (GFR \\\u003C 90 ml\u002F(min•1.73m²));\n* Exploratory surgeries, day surgeries, or surgeries that only involve opening and closing the abdomen;\n* Blood pressure ≥180\u002F110 mmHg at rest (≥Grade 3 hypertension according to the 2020 ISH Hypertension Guidelines); or systolic blood pressure \\\u003C90 mmHg or mean blood pressure \\\u003C65 mmHg;\n* Patients participated in other drug trials within the past 3 months;\n* Patients with communication difficulties, inability to understand pain scores or patient-controlled intravenous analgesia;\n* Patients with consciousness disorders or other psychiatric illnesses;\n* Patients with a confirmed or suspected history of substance abuse or long-term use of anesthetic sedatives and analgesics;\n* Cancer patients have received neoadjuvant treatment or chemotherapy preoperatively;\n* Allergic to the drugs used in this trial and their components.","ALL","18 Years","65 Years",{"count":21,"type":22},1316,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if the administration of oxycodone for preventive analgesia works to reduce the chronification of acute postoperative pain in adult participants undergoing major abdominal surgery. The main question it aims to answer is:\n\n• Does administration of oxycodone before surgical incision reduce the occurrence of chronic pain or relieve the chronic pain symptoms 3 months after the operation? Researchers will compare oxycodone + parecoxib sodium to placebo + parecoxib sodium combinations to see if oxycodone works to reduce the chronification of acute postoperative pain.\n\nParticipants will:\n\n* Take oxycodone + parecoxib sodium or placebo + parecoxib sodium combinations before the surgical incision\n* Cooperate with the follow-up staffs and complete some checkups or tests within 3 months after the operation.",[28,29],"Oxycodone","Chronic Pain, Postoperative",[28,31,32],"Preventive analgesia","Chronification of acute postoperative pain","NOT_YET_RECRUITING","2024-12-03",{"date":36,"type":37},"2024-12-09","ACTUAL",{"date":39,"type":22},"2025-01-01",{"date":41,"type":22},"2027-04-30",{"name":43,"class":44},"Ailin Luo","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100567197","evaluating-the-analgesic-efficacy-of-oxycodone-hydrochloride-in-pediatric-laparoscopic-cryptorchidism-surgery-100567197","NCT06665048","Evaluating the Analgesic Efficacy of Oxycodone Hydrochloride in Pediatric Laparoscopic Cryptorchidism Surgery","Anesthesia","Inclusion Criteria:\n\n* Age range: patients between 1 and 6 years old who are scheduled to undergo cryptorchid surgery.\n* No severe cardiopulmonary dysfunction, able to tolerate endotracheal intubation and general anesthesia.\n* Children who have not received long-term analgesic medication before surgery.\n* Children with a BMI range of 18.5-24 kg\u002Fm2.\n\nExclusion Criteria:\n\n* History of allergy to oxycodone hydrochloride, fentanyl or other research-related drugs.\n* Children who have severe pain or need long-term analgesic treatment.\n* Combined with other serious diseases, such as malignant tumors, nervous system diseases, severe infections, coagulation disorders, congenital heart disease or other congenital malformations, and any other diseases that may interfere with the results of the study.\n* Children who have received medication that may affect the evaluation of analgesic effects (such as other analgesics, sedatives, antidepressants, etc.) within two weeks before surgery.\n* There are other situations that are not suitable for participation in this study, such as the child or family members cannot cooperate to complete the research requirements and may not be able to keep in touch during the study.","1 Year","6 Years",{"count":55,"type":22},162,[25],"Cryptorchidism surgery is a common pediatric procedure, often performed laparoscopically to reposition undescended testes into the scrotum. This technique involves manipulation and traction of the spermatic cord, which can lead to emergence agitation and short-term postoperative pain. Managing these symptoms effectively is essential for enhancing perioperative comfort and supporting faster recovery in children.\n\nOxycodone hydrochloride, a newer opioid with established analgesic effects in adult surgery, has been less studied in pediatric contexts. This randomized controlled trial aims to evaluate the effects of administering 0.1 mg\u002Fkg oxycodone hydrochloride 30 minutes before the end of laparoscopic cryptorchidism surgery in children aged 1 to 6. The study will assess outcomes such as anesthesia emergence time, extubation time, incidence of emergence agitation, postoperative analgesia, and nausea and vomiting. The goal is to determine if oxycodone hydrochloride could be an effective choice for pain relief in pediatric laparoscopic surgery, potentially reducing pain and complications, and providing clinical evidence to optimize anesthesia management for safer and more satisfactory pediatric surgical care.\n\nThis research aspires to contribute to the guidelines for pediatric anesthesia, offering a scientific basis for the clinical application of oxycodone hydrochloride in children.",[50,28,59],"Analgesia, Postoperative",[61,28,62],"anesthesia","Analgesia, postoperative","2024-10-28",{"date":65,"type":37},"2024-10-30",{"date":67,"type":22},"2024-12-01",{"date":69,"type":22},"2026-06-01",{"name":71,"class":44},"Shantou University Medical College",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100557183","sequential-method-determination-of-oxycodone-for-thoracoscope-surgery-median-effective-dose-of-acute-pain-treatment-100557183","NCT06534801","Sequential Method Determination of Oxycodone for Thoracoscope Surgery Median Effective Dose of Acute Pain Treatment","Inclusion Criteria:\n\n1. The first unilateral thoracoscopic lobectomy was performed under general anesthesia\n2. age 18- 80 years old\n3. American Society of Anesthesiologists (ASA) physical status I-III\n4. Sign the informed consent of the patients\n\nExclusion Criteria:\n\n1. Moderate to severe obesity (i.e., BMI \\> 30kg\u002Fm2)\n2. Allergic or hypersensitive reaction to oxycodon\n3. A history of chronic pain\n4. Patients with significant heart, pulmonary, liver or renal disease","80 Years",{"count":81,"type":22},60,[25],"The goal of this clinical trial is to measure the median effective dose of oxycodone for the treatment of acute pain after thoracoscopic lobectomy. This clinical trial was divided into two groups based on age, Group I (Age \\\u003C 65 years old) and Group II (Age ≥65 years old). We used the sequential allocation designed by Dixon. The initial oxycodone dose was set to 0.1 mg\u002Fkg.A satisfactory or an unsatisfactory analgesic response of the previous patient determined, respectively, the relative 10% decrease or increase in the dose of oxycodone the next patient received in the same group. The patient before the first crossover point was included as the first case for ED50 estimation in each group.The study was conducted until 7 crossover points were collected",[28,85,86],"Thoracoscopic Lobectomy","Acute Postoperative Pain","2024-08-01",{"date":89,"type":37},"2024-08-02",{"date":91,"type":22},"2024-09-01",{"date":93,"type":22},"2026-04-01",{"name":95,"class":44},"Jianbo Wu",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":72},"100500378","effects-of-oxycodone-combined-with-pregabalin-on-chronic-postsurgical-pain-in-spinal-surgery-100500378","NCT05795478","Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery","Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery: a Randomized Control, Double-blinded, Factorial Design Trial","Inclusion Criteria:\n\n* Patient undergoing elective spinal surgery\n* Ages equal to or more than 18 years old\n* ASA I-III\n* Signed informed consent\n\nExclusion Criteria:\n\n* Previous allergic history to gabapentinoids or oxycodone;\n* Patients with aphasia or inability to cooperate with scales assessments;\n* Patients with a diagnosed history of psychiatric disorder;\n* Known severe insufficiency of vitals(such as heart failure\u002Frenal dysfunction\u002Fhepatic failure);\n* Patients treated with gabapentin\u002Fpregabalin in the last three months;\n* History of drug abuse;\n* Body Mass Index more than 35 kg\u002F㎡;\n* Pregnant or breastfeeding woman.",{"count":104,"type":22},264,[25],"Chronic postoperative pain is one of the common perioperative complications, which seriously affects the prognosis of patients. Currently, no specific perioperative pain management strategy has been found to be effective in preventing and treating chronic postoperative pain in patients undergoing spinal surgery. At present, oxycodone has been widely recognized in different surgical populations for the control of acute postoperative pain, but its contribution to chronic postoperative pain remains unknown. Meanwhile, whether pregabalin can reduce the occurrence of chronic postoperative pain remains controversial, and whether the combination of the two drugs can control the occurrence of chronic postoperative pain in a more comprehensive way remains unknown. Therefore, we intend to conduct this randomized-controlled, factorial design study to determine the efficacy and safety of oxycodone combined with pregabalin in the treatment of chronic postoperative pain in patients undergoing spinal surgery.",[108,28,109,110],"Chronic Post Operative Pain","Pregabalin","Postoperative Complications","RECRUITING","2024-07-31",{"date":87,"type":37},{"date":115,"type":37},"2023-10-24",{"date":117,"type":22},"2024-12-31",{"name":119,"class":44},"Beijing Tiantan Hospital",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":72},"100550278","phase-4-efficacy-and-safety-of-oxycodone-hydrochloride-for-long-term-analgesia-in-icu-patients-100550278","NCT06444997","Efficacy and Safety of Oxycodone Hydrochloride for Long-term Analgesia in ICU Patients","Efficacy and Safety of Oxycodone Hydrochloride and Remifentanil for Long-term Analgesia During Invasive Mechanical Ventilation in Postoperative Patients: A Pilot Study","Inclusion Criteria:\n\n* 18 ≤ Age ≤ 80\n* Intubated and mechanically ventilated \\< 3 days prior to enrollment\n* Expected need for continuous mechanical ventilation ≥ 24 hours\n\nExclusion Criteria:\n\n* Patients requiring deep sedation (e.g., mechanical ventilation patients with severe man-machine dyssynchrony, respiratory distress due to severe respiratory failure, application of neuromuscular blockers, status epilepticus, surgical procedures requiring strict immobilization, mild hypothermia treatment, etc.);\n* Chronic kidney disease, severe liver dysfunction (Child-Pugh Class C)\n* Severe shock requiring norepinephrine ≥ 0.5 µg\u002Fkg\u002Fmin\n* American Society of Anesthesiologists (ASA) Class 5 patients (near death)\n* Nerve injury or organic pathological changes in the brain\n* Need for designated sedatives or anesthetics other than study drug during treatment\n* Patients with chronic pain, frequently taking strong opioids, such as morphine\n* History of alcohol or drug abuse\n* Participation in other opioid studies within 30 days\n* Pregnant or lactating women\n* Patients with study drug allergy and contraindications Patients who are not suitable for inclusion in the study as judged by the investigator",{"count":81,"type":22},[129],"PHASE4","The goal of this clinical trial is to learn if oxycodone hydrochloride works to manage pain in patients requiring mechanical ventilation. It will also assess the safety of oxycodone hydrochloride. The main questions it aims to answer are:\n\n1. Does oxycodone hydrochloride effectively lower the CPOT (Critical Care Pain Observation Tool) score in mechanically ventilated patients?\n2. What medical problems do participants have when using oxycodone hydrochloride? Researchers will compare oxycodone hydrochloride to remifentanil to see if oxycodone works better to manage pain in these patients.\n\nParticipants will:\n\n* Receive either oxycodone hydrochloride injection at a dose of 0.03-0.2 mg\u002Fkg\u002Fh or remifentanil injection at a dose of 2-9 μg\u002Fkg\u002Fh.\n* Have their pain scores assessed every 15 minutes until the CPOT score is less than 3. After reaching the target pain score, assessments will be done every 4 hours.\n* Have their vital signs and monitoring data recorded.\n* Have analgesia and sedation scores recorded from days 1 to 7 after administration, with drug dosages adjusted based on pain scores.\n* Have the incidence of adverse reactions and changes in gastrointestinal function observed and recorded from days 1 to 7 after administration.\n* If extubated within 7 days, relevant data will be collected based on the time of extubation.\n* Be followed up on day 28 through the electronic medical record system to gather data on the extubation success rate and incidence of complications within the 28-day period.",[28,132,133,134,135],"Analgesia","Mechanical Ventilation","Postoperative","Remifentanil",[28,137,138,132,133,135,139,140],"oxycodone hydrochloride","long term analgesic","Pilot Study","ICU","2024-06-05",{"date":143,"type":37},"2024-06-06",{"date":145,"type":22},"2024-06-01",{"date":147,"type":22},"2025-12-31",{"name":149,"class":44},"Shanghai Zhongshan Hospital"]